Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced or Metastatic ER+ Breast Cancer 1

Interventions

Cyclophosphamide 627pembrolizumab 506Paclitaxel 455Gemcitabine 439Carboplatin 438Cisplatin 421Radiotherapy 382fludarabine 368Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 246Fluorouracil 229Dexamethasone 225Specimen Handling 224Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Biopsy 198Temozolomide 197Ipilimumab 197fludarabine phosphate 195Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Injections 171Cetuximab 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × LSZ102 × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡